Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.drreddys.com | |
Market Cap | 91,199.58 Cr. | |
Enterprise Value(EV) | 90,816.58 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 283.19 | Trailing Twelve Months Ending 2023-06 |
Price-Earning Ratio (PE) | 19.31 | Trailing Twelve Months Ending 2023-06 |
Industry PE | 37.33 | Trailing Twelve Months Ending 2023-06 |
Book Value / Share | 1,471.47 | Trailing Twelve Months Ending 2023-06 |
Price to Book Value | 3.72 | Calculated using Price: 5,468.10 |
Dividend Yield | 0.73 | Period Ending 2023-03 |
No. of Shares Subscribed | 16.68 Cr. | 166,784,764 Shares |
FaceValue | 5 | |
About Dr. Reddy's Laboratories Ltd. | ||
The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations. |
1 Day |
|
+0.53% |
1 Week |
|
-4.52% |
1 Month |
|
-5.37% |
3 Month |
|
+9.50% |
6 Month |
|
+22.54% |
1 Year |
|
+32.10% |
2 Year |
|
+14.09% |
5 Year |
|
+109.73% |
10 Year |
|
+124.91% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 26.63 | 18.95 | 10.20 | 7.40 | 14.75 | 13.76 | 11.82 | 11.93 | 21.36 | |
Return on Capital Employed (%) | 22.70 | 19.55 | 9.77 | 8.21 | 13.66 | 11.12 | 15.49 | 14.59 | 26.22 | |
Return on Assets (%) | 13.67 | 11.05 | 6.14 | 4.23 | 8.86 | 9.20 | 8.21 | 8.08 | 15.01 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Shh. Funds | 7,865 | 9,853 | 12,570 | 12,262 | 12,572 | 14,024 | 15,599 | 17,642 | 19,212 | 23,286 | |
Non Curr. Liab. | 2,182 | 1,678 | 877 | 456 | 2,538 | 2,113 | -808 | -197 | -508 | -278 | |
Curr. Liab. | 5,790 | 6,821 | 6,347 | 8,420 | 6,894 | 5,897 | 7,214 | 8,104 | 9,766 | 8,572 | |
Minority Int. | |||||||||||
Equity & Liab. | 15,838 | 18,353 | 19,794 | 21,138 | 22,004 | 22,034 | 22,005 | 25,548 | 28,470 | 31,580 | |
Non Curr. Assets | 5,512 | 6,476 | 8,000 | 11,454 | 11,505 | 10,924 | 9,406 | 10,998 | 10,682 | 11,264 | |
Curr. Assets | 10,326 | 11,877 | 11,794 | 9,684 | 10,498 | 11,110 | 12,599 | 14,535 | 17,788 | 20,316 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 15,838 | 18,353 | 19,794 | 21,138 | 22,004 | 22,034 | 22,005 | 25,548 | 28,470 | 31,580 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
Net Sales | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 26,195 | |
Other Income | 275 | 295 | 172 | 155 | 338 | 621 | 291 | 485 | 1,056 | 412 | |
Total Income | 15,298 | 15,863 | 14,368 | 14,436 | 15,786 | 18,138 | 19,339 | 22,030 | 25,725 | 26,607 | |
Total Expenditure | -11,530 | -11,983 | -11,724 | -11,930 | -12,270 | -15,047 | -15,178 | -17,778 | -18,321 | -18,761 | |
PBIDT | 3,769 | 3,880 | 2,644 | 2,506 | 3,516 | 3,091 | 4,161 | 4,252 | 7,405 | 7,845 | |
Interest | -109 | -83 | -63 | -79 | -89 | -98 | -97 | -96 | -143 | -145 | |
Depreciation | -760 | -939 | -1,027 | -1,077 | -1,135 | -1,163 | -1,229 | -1,165 | -1,250 | -1,302 | |
Taxation | -563 | -751 | -297 | -438 | -386 | 140 | -932 | -879 | -1,541 | -1,707 | |
Exceptional Items | |||||||||||
PAT | 2,336 | 2,108 | 1,257 | 912 | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 4,691 | |
Minority Interest | |||||||||||
Share Associate | 23 | 35 | 34 | 32 | |||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 4,723 | |
Adjusted EPS | 137 | 125 | 78 | 57 | 117 | 122 | 117 | 131 | 271 | 284 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 1,970 | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | 5,888 | |
Cash Fr. Inv. | -1,694 | -2,265 | -2,039 | -1,840 | -1,488 | -773 | -492 | -2,266 | -2,639 | -4,137 | |
Cash Fr. Finan. | -24 | -433 | -1,700 | -369 | -444 | -2,133 | -2,516 | -30 | -242 | -2,686 | |
Net Change | 251 | -174 | -477 | -65 | -129 | -35 | -24 | 1,275 | -70 | -936 | |
Cash & Cash Eqvt | 862 | 583 | 492 | 378 | 254 | 223 | 196 | 1,482 | 1,485 | 578 |
Tue, 26 Sep 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share certificate |
Fri, 22 Sep 2023
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ending On September 30 2023. DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2023. |
Wed, 20 Sep 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Letter of confirmation in lieu of share certificate(s) reported lost/misplaced |
Tue, 26 Sep 2023 |
|
|
|
|
|